ArticleNeuroscience applied2024
Chronic activation of the small-conductance, calcium-activated potassium channel precipitates age-dependent depressive-like behavior and cognitive deficits and reduces klotho concentration.
Article in Neuroscience applied, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- KAlcohol (Fayetteville, N.Y.) · 2025Article
- ADHD detection based on human action recognition.Neuroscience applied · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a common mood disorder with a multifaceted, complex pathophysiology. An abnormal level of corticosteroids in the brain can cause structural change in the hippocampus. It may cause an imbalance in calcium homeostasis leading to functional impairment in the activity of the voltage-insensitive, small conductance, calcium-activated potassium channel (SKC). Deficit in the longevity protein klotho is also implicated in stress-induced depression. We ascertained whether chronic activation of SKCs can cause age-dependent depressive-like behavior and cognitive deficits, accompanied by disturbances in klotho concentration. We tested the effect of repeated activation of SKCs by the potent SKC agonist, 1-EBIO (1.0 mg/kg, IP, once daily for 15 days) in young (3 months) and mid-life (12 months) male BALB/c mice. We conducted a battery of behavioral tests to investigate depressive-like behavior and cognitive functions. Then, we used an enzyme-linked immunosorbent assay (ELISA) on brain homogenates to determine the change in total klotho concentration in the prefrontal cortex, hippocampus, and dorsal raphe. We found that chronic 1-EBIO treatment decreased locomotor activity, sucrose preference, and alternation index in an age-dependent manner. The drug does not affect stress-coping behavior in the forced swim test. The behavioral deficits were accompanied by a significant decrease in total klotho concentration in the hippocampus but not in the prefrontal cortex or dorsal raphe, observed in an age-dependent manner. Based on these results, we surmise that chronic activation of SKCs results in concurrent cognitive and depressive-like phenotypes in mid-aged mice. Therefore, this could represent a putative therapeutic target for age-related psycho-affective disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.